sanofi-aventis endocrine, cardiovascular, cancer news

sanofi-aventis said it will restructure and reduce headcount by about 1,700 (25%) to 5,200 at its U.S. Pharmaceutical Operations division to streamline operations. The pharma said it will move resources from its late life-cycle products to focus on diabetes, atrial fibrillation (AF) and oncology. The pharma said decisions on the restructuring will be finalized in mid-December. sanofi said the restructuring is part of an €2 billion ($2.8 billion) cost reduction plan announced last year. ...